Navigation Links
First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
Date:12/16/2010

LAWRENCE, Mass., Dec. 16, 2010 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System One™, the only hemodialysis machine cleared by the FDA for home use. Each of these patients continues to experience the improved health and quality of life benefits possible with more frequent home hemodialysis using the System One.

As early adopters of daily home hemodialysis with the NxStage System One, each of the patients arrived at the decision to try NxStage at various stages in his treatment for end stage renal disease (ESRD). These patients--Craig, Carl, and Everette--began treatment with the NxStage System One in December, 2003 as part of NxStage's groundbreaking clinical trial for its home indication.

Everette had been undergoing in-center dialysis treatments when he learned about daily home hemodialysis with NxStage. "For the past seven years, the NxStage System One has given me the freedom to live my life closer to the way I want to live it and allowed me to dedicate more time to my hobbies and business dreams," he said.  "Thanks in part to NxStage and dialyzing more frequently, I feel more healthy and active. I've come off several blood pressure medications and play basketball twice a week while spearheading my online clothing store."

"This is a tremendous milestone not only for these patients, but also for all of our patients, prescribing nephrologists, partners and employees," stated Jeffrey H. Burbank, founder and CEO of NxStage Medical, Inc. "We are extremely gratified to see these patients thriving and are excited to expand access to the life changing benefits possible with more frequent home hemodialysis using the System One to a growing number of patients worldwide."  

You can read more about these patients and others on the NxStage website at http://www.nxstage.com/our_community/chronic_community/patients/patient_stories.cfm.

About NxStage Medical, Inc.NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage's website at www.nxstage.com.

The patient testimonials included in this release are examples of patient experiences on home daily hemodialysis with the NxStage System One. All patient experiences will vary, and there can be no assurance that all patients will experience these benefits. All hemodialysis involves some risk, and patients are encouraged to speak with their physicians to see if home dialysis with the NxStage System One is right for them.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage's Quarterly Report on Form 10-Q for the period ended September 30, 2010 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.com
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Radiology Introduces Baltimores First 1.2T High Field Open MRI
2. Pfizer Declares A 20-Cent First-Quarter 2011 Dividend
3. Lilly Declares First-Quarter 2011 Dividend
4. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
5. Netsmart Technologies is First Behavioral Healthcare Software Provider to Attain Complete ARRA-Certified Electronic Health Record
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
8. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
9. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
10. BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States
11. First-Line Use of Abilify Has More Than Doubled Over the Past Year for the Treatment of Newly-Diagnosed Patients in Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
Breaking Medicine Technology:
(Date:5/28/2017)... Haven, FL (PRWEB) , ... May 28, 2017 ... ... Partners of America (PPOA), is proud to announce that Sheldon K. Cho, MD, ... comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques to ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing ... The three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New ... brand and network of independent hearing healthcare providers to help them stay ahead in ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... new educational seminar to focus on current legislative activity and the latest regulatory ... at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical ... “We are thrilled to partner with Cupron® to provide customers with a ...
(Date:5/26/2017)... ... 2017 , ... Rob Lowe acts as host and helps educate and inform ... hiking in American. Viewers can reconnect with America as it explores some of the ... consumers have looked for an inventive new place for a family vacation, and have ...
Breaking Medicine News(10 mins):